Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6274 posts found.

Oryzon Genomics announces publication of phase 2a ALICE trial results

June 4, 2024 Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial

Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
News

CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment

June 3, 2024 Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …
News

AbbVie gains positive CHMP opinion for Skyrizi for treatment of UC

May 31, 2024 Medical Communications AbbVie, EMA, Gastrointestinal tract, Skyrizi, ulcerative colitis

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
News

Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases

May 30, 2024 Medical Communications Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand …
News

Full-Life Technologies’ IND application for prostate cancer cleared by FDA

May 30, 2024 Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer

Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …
News

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024 Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024 Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
News

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024 Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
News

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024 Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …
News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024 Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
News

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024 Medical Communications Amgen, FDA, Oncology, lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …
News

FDA approves Roche’s HPV self-collection screening option

May 15, 2024 Medical Communications FDA, HPV, Oncology, Roche, cervical cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
News

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024 Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
News

Moderna shares update on RSV vaccine

May 13, 2024 Medical Communications FDA, Immunology, Moderna, Vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …
News

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024 Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024